AR093457A1 - Derivados de bendamustina y metodos para utilizarlos - Google Patents

Derivados de bendamustina y metodos para utilizarlos

Info

Publication number
AR093457A1
AR093457A1 ARP130104160A ARP130104160A AR093457A1 AR 093457 A1 AR093457 A1 AR 093457A1 AR P130104160 A ARP130104160 A AR P130104160A AR P130104160 A ARP130104160 A AR P130104160A AR 093457 A1 AR093457 A1 AR 093457A1
Authority
AR
Argentina
Prior art keywords
methods
bendamustine
bendamustine derivatives
derivatives
amides
Prior art date
Application number
ARP130104160A
Other languages
English (en)
Spanish (es)
Inventor
P Bakale Roger
Chen Jian
Y Labell Rachel
R Patel Piyush
d brown Peter
S Drager Anthony
E Mkean Robert
C Roemmele Renee
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of AR093457A1 publication Critical patent/AR093457A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP130104160A 2012-11-12 2013-11-12 Derivados de bendamustina y metodos para utilizarlos AR093457A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261725213P 2012-11-12 2012-11-12
US201361776951P 2013-03-12 2013-03-12

Publications (1)

Publication Number Publication Date
AR093457A1 true AR093457A1 (es) 2015-06-10

Family

ID=49667594

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130104160A AR093457A1 (es) 2012-11-12 2013-11-12 Derivados de bendamustina y metodos para utilizarlos

Country Status (17)

Country Link
US (7) US9452988B2 (cg-RX-API-DMAC10.html)
EP (1) EP2917183A1 (cg-RX-API-DMAC10.html)
JP (1) JP6262246B2 (cg-RX-API-DMAC10.html)
KR (1) KR20150086308A (cg-RX-API-DMAC10.html)
AR (1) AR093457A1 (cg-RX-API-DMAC10.html)
AU (1) AU2013342015B2 (cg-RX-API-DMAC10.html)
BR (1) BR112015010501A2 (cg-RX-API-DMAC10.html)
CA (1) CA2890462A1 (cg-RX-API-DMAC10.html)
CL (1) CL2015001246A1 (cg-RX-API-DMAC10.html)
EA (1) EA029706B1 (cg-RX-API-DMAC10.html)
HK (2) HK1215701A1 (cg-RX-API-DMAC10.html)
IL (1) IL238662A (cg-RX-API-DMAC10.html)
MX (1) MX2015005805A (cg-RX-API-DMAC10.html)
PH (1) PH12015501024A1 (cg-RX-API-DMAC10.html)
SG (1) SG11201503560TA (cg-RX-API-DMAC10.html)
TW (1) TWI598341B (cg-RX-API-DMAC10.html)
WO (1) WO2014075035A1 (cg-RX-API-DMAC10.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR122019024201B1 (pt) 2010-05-20 2021-08-03 Array Biopharma Inc Composto macrocíclico como inibidores de trk quinase, seu uso, e composição farmacêutica
EP2917183A1 (en) * 2012-11-12 2015-09-16 Ignyta, Inc. Bendamustine derivatives and methods of using same
CA2904143A1 (en) 2013-03-12 2014-10-09 Cephalon, Inc. Nanoparticulate and macroparticulate formulations
CA2992586A1 (en) 2015-07-16 2017-01-19 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
EP3484519A1 (en) * 2016-07-13 2019-05-22 Cephalon, Inc. Pharmaceutical prodrugs and methods of their preparation and use
TWI752098B (zh) 2016-10-10 2022-01-11 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
JP6888101B2 (ja) 2017-01-18 2021-06-16 アレイ バイオファーマ インコーポレイテッド ＲＥＴキナーゼ阻害剤としての置換ピラゾロ［１，５−ａ］ピラジン化合物
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
TWI876442B (zh) 2017-10-10 2025-03-11 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
EP3740491A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
EP3740486A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
CN111630054B (zh) 2018-01-18 2023-05-09 奥瑞生物药品公司 作为RET激酶抑制剂的取代的吡唑并[3,4-d]嘧啶化合物
CA3108065C (en) 2018-07-31 2025-10-07 Loxo Oncology, Inc. SPRAY-DRIED DISPERSIONS, FORMULATIONS AND POLYMORPHIES OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)(1,1,1-TRIFLUOROPROPANE-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE
ES2922314T3 (es) 2018-09-10 2022-09-13 Array Biopharma Inc Compuestos heterocíclicos condensados como inhibidores de cinasa RET

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681964A (en) * 1990-10-23 1997-10-28 University Of Kentucky Research Foundation Permeable, non-irritating prodrugs of nonsteroidal and steroidal agents
US5834025A (en) 1995-09-29 1998-11-10 Nanosystems L.L.C. Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
US7089218B1 (en) 2004-01-06 2006-08-08 Neuric Technologies, Llc Method for inclusion of psychological temperament in an electronic emulation of the human brain
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
CA2428018A1 (en) * 2000-12-01 2002-06-06 Enzon, Inc. Tetrapartate prodrugs
WO2003086369A2 (en) * 2002-04-05 2003-10-23 Valorisation-Recherche, Societe En Commandite Stealthy polymeric biodegradable nanospheres and uses thereof
DK1585548T3 (en) 2002-12-09 2018-09-03 Abraxis Bioscience Llc COMPOSITIONS AND PROCEDURES FOR THE DELIVERY OF PHARMACOLOGICAL AGENTS
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
CN103169729A (zh) 2005-02-18 2013-06-26 阿布拉科斯生物科学有限公司 治疗剂的组合和给予方式以及联合治疗
DE102005062440B4 (de) * 2005-12-27 2011-02-24 Lts Lohmann Therapie-Systeme Ag Proteinbasiertes Trägersystem zur Resistenzüberwindung von Tumorzellen
CN101878024B (zh) 2007-11-28 2014-04-09 塞拉特药物股份有限公司 改良的紫杉烷递送系统
AR072777A1 (es) 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
CN104224703A (zh) * 2008-09-25 2014-12-24 赛福伦公司 苯达莫司汀的液体配制品
US9149441B2 (en) * 2008-09-29 2015-10-06 The Corporation Of Mercer University Nanospheres encapsulating bioactive material and method for formulation of nanospheres
MX2011003751A (es) * 2008-10-08 2011-04-27 Cephalon Inc Procesos para preparar bendamustina.
NZ592970A (en) * 2008-12-03 2013-05-31 Astellas Deutschland Gmbh Oral dosage forms of bendamustine
AU2011260615B2 (en) 2010-06-02 2016-11-17 Pharma& Schweiz Gmbh Oral dosage forms of bendamustine
TWI455722B (zh) 2010-06-04 2014-10-11 Pfizer Vaccines Llc 用於預防或治療菸鹼成癮之共軛體
CN101966158A (zh) 2010-09-28 2011-02-09 上海丽思化工科技有限公司 一种注射用盐酸苯达莫司汀冻干粉针剂及其制备方法
US20130217888A1 (en) 2010-11-01 2013-08-22 Shailpa Medicare Limited Process for preparing bendamus tine hydrochloride monohydrate
DE102010055499A1 (de) * 2010-12-22 2011-06-16 W.C. Heraeus Gmbh Prozess zur Herstellung von Bendamustinalkylester, Bendarmustin sowie Derivaten davon
HUE048876T2 (hu) 2011-05-09 2020-08-28 Mayo Found Medical Education & Res Rákos megbetegedések kezelése
US9308276B2 (en) 2011-05-17 2016-04-12 University Of South Alabama Combination therapy for treatment of cancer
ES2613838T3 (es) 2011-09-26 2017-05-26 Fresenius Kabi Oncology Ltd Un procedimiento mejorado para la preparación de hidrocloruro de bendamustina
PT2656843E (pt) 2012-04-26 2015-04-14 Helmut Schickaneder Ésteres de bendamustina e compostos relacionados e a sua utilização médica
UA117809C2 (uk) 2012-06-19 2018-10-10 Хельмут Шикканедер Похідні бендамустину, споріднені сполуки та їхнє медичне застосування для лікування раку
US9314532B2 (en) 2012-08-10 2016-04-19 University Of North Texas Health Science Center Drug delivery vehicle
EP2917183A1 (en) * 2012-11-12 2015-09-16 Ignyta, Inc. Bendamustine derivatives and methods of using same

Also Published As

Publication number Publication date
US9913827B2 (en) 2018-03-13
KR20150086308A (ko) 2015-07-27
HK1215701A1 (zh) 2016-09-09
CN105051016A (zh) 2015-11-11
BR112015010501A2 (pt) 2017-07-11
TWI598341B (zh) 2017-09-11
EA201590925A1 (ru) 2015-09-30
US9149464B2 (en) 2015-10-06
CA2890462A1 (en) 2014-05-15
EP2917183A1 (en) 2015-09-16
US9630926B2 (en) 2017-04-25
AU2013342015A1 (en) 2015-05-28
US20160289198A1 (en) 2016-10-06
US20150232427A1 (en) 2015-08-20
WO2014075035A1 (en) 2014-05-15
US20160016912A1 (en) 2016-01-21
EA029706B1 (ru) 2018-05-31
JP2015536996A (ja) 2015-12-24
SG11201503560TA (en) 2015-06-29
AU2013342015B2 (en) 2016-11-24
US20180147186A1 (en) 2018-05-31
IL238662A (en) 2017-08-31
PH12015501024A1 (en) 2015-07-27
CL2015001246A1 (es) 2016-01-15
HK1212977A1 (zh) 2016-06-24
IL238662A0 (en) 2015-06-30
US9150517B2 (en) 2015-10-06
TW201439069A (zh) 2014-10-16
JP6262246B2 (ja) 2018-01-17
US9452988B2 (en) 2016-09-27
US20150274675A1 (en) 2015-10-01
US20150246023A1 (en) 2015-09-03
MX2015005805A (es) 2016-04-15
US20170182008A1 (en) 2017-06-29

Similar Documents

Publication Publication Date Title
ECSP24031979A (es) Compuestos terapéuticamente activos y sus métodos de uso
CY1122266T1 (el) Ενωσεις 3-αμινοκυκλοαλκυλιου ως ror-gamma-t αναστολεις και χρησεις αυτων
MX367389B (es) Compuestos y sus metodos de empleo.
CL2015003395A1 (es) Derivados pirazolopirrolidina y su uso en el tratamiento de la enfermedad
CL2017002483A1 (es) Compuestos heterocíclicos como inhibidores de lsd1
CR20150571A (es) Compuestos y composiciones terapéuticos
CR20210079A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
UA116648C2 (uk) Фумарати як проліки та їх застосування при лікуванні різних захворювань
MX2017002824A (es) Inhibidores demetilasa-1 especifica de lisina.
MX376008B (es) Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide.
ECSP14012726A (es) Compuestos terapéuticamente activos y sus métodos de uso
MX2017000179A (es) Inhibidores de demetilasa-1 especifica de lisina.
CR20140468A (es) Inhibidores de diacilglicerol aciltransferasa 2
PH12015501024A1 (en) Bendamustine derivatives and methods of using same
MX2016007585A (es) Inhibidores de desmetilasa-1 especifica de lisina.
CO7350620A2 (es) Nuevos derivados de piridina
UY35898A (es) ?compuestos inhibidores de syk y composiciones que los comprenden?.
UY34523A (es) Derivados de betulina
CR20150470A (es) Derivados de triazolona de piridinilo y piridinilo fusionado
UY33884A (es) Inhibición de la il17 y del ifn-gamma para el tratamiento de las inflamaciones autoinmunes
UY34538A (es) Heteroarilos y usos de los mismos
CR20150447A (es) Nuevos derivados de pirazol
MX2016006975A (es) Compuestos, composicion farmaceutica y metodos para su uso en el tratamiento de enfermedades inflamatorias.
MX2014011583A (es) Metodos y composiciones para el tratamiento de la familia de tumores del sarcoma de ewing.
MX2013014708A (es) Compuestos que inhiben el glioblastoma y su uso.

Legal Events

Date Code Title Description
FB Suspension of granting procedure